Trials / Conditions / Stage IV Mycosis Fungoides/Sezary Syndrome

Stage IV Mycosis Fungoides/Sezary Syndrome

24 registered clinical trials studyying Stage IV Mycosis Fungoides/Sezary Syndrome.

Status	Trial	Sponsor	Phase
Completed	Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies NCT01273766	Wake Forest University Health Sciences	Phase 2
Active Not Recruiting	Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic NCT01199562	City of Hope Medical Center	—
Completed	RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors NCT01158274	National Cancer Institute (NCI)	Phase 1
Completed	AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lympho NCT01129193	Amir Mortazavi	Phase 1
Completed	Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Canc NCT01053494	Wake Forest University Health Sciences	N/A
Terminated	Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer NCT01044745	University of Nebraska	Phase 2
Completed	FAU in Treating Patients With Advanced Solid Tumors or Lymphoma NCT00769288	National Cancer Institute (NCI)	Phase 1
Completed	Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory NCT00601718	University of Washington	Phase 1 / Phase 2
Completed	Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction NCT00499811	National Cancer Institute (NCI)	Phase 1
Completed	Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem NCT00489203	Fred Hutchinson Cancer Center	Phase 2
Completed	3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma NCT00293345	National Cancer Institute (NCI)	Phase 1
Terminated	PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid NCT00354185	National Cancer Institute (NCI)	Phase 1
Completed	PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas NCT00348985	National Cancer Institute (NCI)	Phase 1
Terminated	Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas NCT00096005	National Cancer Institute (NCI)	Phase 1
Completed	MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas NCT00098891	National Cancer Institute (NCI)	Phase 1
Completed	17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas NCT00089271	National Cancer Institute (NCI)	Phase 1
Completed	Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma NCT00077155	National Cancer Institute (NCI)	Phase 1
Terminated	Interleukin-12 and Interleukin-2 in Treating Patients With Mycosis Fungoides NCT00052377	National Cancer Institute (NCI)	Phase 1 / Phase 2
Completed	Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer NCT00049504	Fred Hutchinson Cancer Center	Phase 2
Completed	Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation NCT00040846	Fred Hutchinson Cancer Center	Phase 2
Completed	Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction NCT00025415	National Cancer Institute (NCI)	Phase 1
Completed	506U78 in Treating Patients With Lymphoma NCT00005080	National Cancer Institute (NCI)	Phase 2
Completed	17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymph NCT00004241	National Cancer Institute (NCI)	Phase 1
Completed	Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma NCT00003970	National Cancer Institute (NCI)	Phase 1